Nektar Therapeutics (NKTR) to Release Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. The firm had revenue of $23.49 million during the quarter, compared to analyst estimates of $17.24 million. During the same period in the prior year, the firm earned ($0.27) earnings per share. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Stock Performance

NASDAQ NKTR opened at $1.22 on Friday. Nektar Therapeutics has a one year low of $0.41 and a one year high of $1.93. The firm has a 50 day simple moving average of $1.28 and a 200-day simple moving average of $1.34. The firm has a market cap of $223.66 million, a price-to-earnings ratio of -1.35 and a beta of 0.60.

Wall Street Analysts Forecast Growth

Separately, BTIG Research restated a “buy” rating and issued a $4.00 price target on shares of Nektar Therapeutics in a research note on Monday, September 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $2.33.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.